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Alveolar epithelial type II
AIPTThe accumulation mechanisms of amiodarone (AMD) involving transporters in lung alveolar epithelial type
II cells were studied. The uptake of AMD was examined using human alveolar epithelial-derived cell line
A549 as a model. AMD was transported by the carrier-mediated system, and the apparent Km and Vmax
values were 66.8±30.3 μM and 49.7±9.7 nmol/mg protein/5 min, respectively. The uptake of AMD by
A549 cells was Na+-independent and was inhibited by substrates of human organic anion transporting
polypeptide (OATP). The inhibition proﬁles were similar to the inhibitory effects of several compounds on
OATP2B1-mediated E-3-S transport, and RT-PCR analysis showed mRNA expression of OATP2B1 and 1B3 in
A549 cells. SiRNAs targeted to the OATP2B1 gene decreased the OATP2B1 mRNA expression level in A549
cells up to about 50% and reduced the uptake of AMD up to about 40%. These results indicate that AMD
uptake mediated by carriers, including OATP2B1, might lead to accumulation of AMD in the lung and AMD-
induced pulmonary toxicity (AIPT).© 2009 Elsevier B.V. All rights reserved.1. IntroductionAmiodarone (AMD) is a benzofurane derivative with class III
antiarrhythmic activity that is effective in controlling intractable
cardiac arrhythmias [1,2]. Clinical evidence suggests that this drug
has a role in reducing the relative risk for arrhythmic or sudden
death and overall mortality in survivors of myocardial infarction and
in heart failure patients [3–7]. Among the various antiarrhythmic
agents, AMD has electrophysiological effects that most closely
approximate those of an ideal antiarrhythmic agent [8]. Although
AMD is used widely [9], there is a risk of development of life-
threatening AMD-induced pulmonary toxicity (AIPT) [10]. AIPT has
been clinically diagnosed in 5 to 10% of patients receiving high doses
of AMD and in 1.6% of patients receiving AMD at a dose of 400 mg/
day or less [11]. Because of its high potential for mortality, AIPT is the
adverse event of greatest concern for patients receiving AMD
therapy.
Several mechanisms responsible for AIPT, including alteration in
inﬂammatory mediator release [12], cell membrane perturbation [13]
and phospholipids promotion [14], have been proposed. It has also
been reported that AMD appears to activate a speciﬁc intracellular
death-related pathway, including passively the bax-dependent cas-
pase-3 activation pathway, and thus induce apoptosis in human lung
epithelial cells [15]. Bolt et al. reported that AMD-induced perturba-
tions of mitochondrial function may initiate AIPT [16].).
ll rights reserved.Thus, the mechanisms of AIPT and AMD-induced cytotoxicity have
been extensively studied. On theother hand, AMDhas a strong tendency
to accumulate in the lung among lean tissues [17–20]. This characteristic
tissue distribution of AMD is also considered as a factor responsible for
the initiation of AIPT, and an uptakemechanism(s) of AMD is presumed
to exist in lung tissue. Although it was believed that AMD absorption is
mediated by a passive diffusion process [21], the second highest rate of
AMD accumulation in the lung after that in adipose tissue cannot be
explained. AMD has been reported to be an inhibitor of P-gp [22,23] and
rat organic anion transporting polypeptide 2 (Oatp2) [23,24], but the
transport mechanisms of AMD itself have not been elucidated.
Thus, we focused on the uptake mechanisms of AMD involving
transporters in lung alveolar epithelial cells. In this study, we
characterized the transport mechanisms of AMD using the human
alveolar epithelial-derived cell line A549, which is usedwidely in AMD
toxicity experiments. We also showed that human organic anion
transporting polypeptide 2B1 (OATP2B1) contributes to AMD uptake
in A549 cells.
2. Materials and methods
2.1. Chemicals
AMDwas kindly supplied by Taisho Pharmaceutical (Tokyo, Japan).
[3H] Estrone-3-sulfate (E-3-S) was purchased from Perkin Elmer
(Waltham, MA). All other reagents were of the highest grade available
and used without further puriﬁcation. AMD was dissolved in
methanol (1% w/v ﬁnal concentration) due to its hydrophobic
properties and poor solubility in water.
Table 1
Primer sequences for RT-PCR and real-time PCR.
Gene Primer sequence Product
size (bp)
Reference
OATP1A2 Forward 5′-AAGACCAACGCAGGATCCAT-3′ 101 [26]
Reverse 5′-GAGTTTCACCCATTCCACGTACA-3′
OATP2B1 Forward 5′-GAGTTTCACCCATTCCACGTACA-3′ 198 [27]
Reverse 5′-GCCACAGGACTCCATGCCT-3′
OATP1B1 Forward 5′-TGTCATTGTCCTTTTACCTATTAT-3′ 195 [28]
Reverse 5′-TGTAAGTTATTCCATTGTTTCCAC-3′
OATP3A1 Forward 5′-CAGGCCATGCTCTCCGAAA-3′ 237 Present study
Reverse 5′-CTGCTGCTCCAGGTACTTCC-3′
OATP4A1 Forward 5′-CTGCCAGCCAGAACACTACA-3′ 216 Present study
Reverse 5′-AGAAGGAGGGGCTTTCTCTG-3′
OATP1B3 Forward 5′-GTCCAGTCATTGGCTTTGCA-3′ 111 [26]
Reverse 5′-CAACCCAACGAGAGTCCTTAGG-3′
Fig. 1. Time course of AMD uptake by A549 cells. The uptake of AMD (25 μM) was
measured at pH 5.0 at 37 °C. Each point represents the mean±S.D. of 3 independent
experiments.
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A549 cells obtained from American Type Culture Collection
(Rockville, MD) were maintained in plastic culture ﬂasks (Falcon,
Becton Dickinson and Co., Lincoln Park, NJ). These stock cells were
subcultivated before reaching conﬂuence. The medium consisted of
Dulbecco's Modiﬁed Eagle's Medium (Sigma) supplemented with 10%
fetal bovine serum (ICN Biomedicals, Inc, Aurora, OH) and 100 IU/mL
penicillin–100 μg/mL streptomycin (Sigma). The monolayer cultures
were grown in an atmosphere of 5% CO2–95% air at 37 °C. The cells
were given fresh growth medium every 2 days. When the A549 cells
had reached conﬂuence, they were harvested with 0.25 mM trypsin
and 0.2% EDTA (0.5–1 min at 37 °C), resuspended, and seeded into a
new ﬂask. For the uptake study, A549 cells were seeded at a cell
density of 1×105 cells/cm2 on 24-well plates (Corning Costar Corp.,
Cambridge, MA). The cell monolayers were fed a fresh growth
medium every 2 days and were used at 4 to 6 days for the uptake
experiments.
2.3. Uptake study in A549 cell monolayers
The uptake of AMDwasmeasured usingmonolayer cultures grown
in 24-well plates. The incubation medium used for the uptake study
was HBSS-MES buffer (pH 5.0) (25 mM D-glucose, 137 mM NaCl,
5.37 mM KCl, 0.3 mM Na2HPO4, 0.44 mM KH2PO4, 1.26 mM CaCl2,
0.8 mM MgSO4 and 10 mM MES). After removal of the growth
medium, cells were preincubated at 37 °C for 10 min with 0.5 mL of
HBSS-MES buffer (pH 5.0). After removal of the medium, 0.5 mL of
incubation medium containing AMD or [3H] E-3-S was added. The
monolayers were incubated for the indicated time at 37 °C. Each cell
monolayer was washed rapidly twice with an ice-cold incubation
medium at the end of the incubation period. To quantify the
concentration of AMD, the cells were solubilized with 0.25 mL of
1 N NaOH and neutralized with 0.25 mL of 1 N HCl. After vortexing
brieﬂy, a part of the mixture (100 μL) was transferred to a fresh tube
and 400 μL MeOH was added. After centrifugation of the mixture
(12,000×g for 10 min), the concentrations of AMD in the supernatant
were measured. To quantify the radioactivity of [3H] E-3-S, the cells
were solubilized in 1% SDS/0.2 N NaOH. The remainder of the sample
was mixed with 8 mL of scintillation cocktail (Amersham Interna-
tional, UK) to measure the radioactivity. All the uptake values were
corrected against protein content.
2.4. RT-PCR analysis
RT-PCR was performed as described previously [25]. Total RNAwas
prepared from A549 cells using an ISOGEN (Nippon Gene, Tokyo) and
an RNase-Free DNase Set (QIAGEN). Single-strand cDNA was made
from 2 μg total RNA by reverse transcription (RT) using a ReverTraAce
(TOYOBO, Japan). Gene-speciﬁc primers for OATP1A2, OATP2B1,OATP1B1, OATP3A1, OATP4A1 and OATP1B3 are shown in Table 1.
For OATP3A1 and OATP4A1, the experimental conditions were
validated by demonstrating the formation of RT-PCR products of the
expected sizes with total RNA of HepG2 cells as a positive control. PCR
was performed using Hot Star Taq PCR (QIAGEN) through 35 cycles of
94 °C for 15 s, 58 °C (for OATP1A2, OATP2B1, OATP3A1, and OATP1B3)
or 55 °C (for OATP1B1 and OATP4A1) for 30 s, and 72 °C for 30 s. The
PCR products were subjected to electrophoresis on a 2% agarose gel
and then visualized by ethidium bromide staining.
2.5. Quantitative real-time PCR
Quantitative real-time PCR was performed as described previously
[25]. Quantitative real-time PCR was performed using an ABI PRISM
7700 sequence detector (Applied Biosystems) with 2×SYBR Green
PCR Master Mix (Applied Biosystems) and speciﬁc primers for
OATP2B1 (sequence shown in Table 1) and GAPDH (forward: 5′-
AAG GTC ATC CCT GAG CTG AA-3′ and reverse: 5′-TTC TAG ACT TCA
TTG CAG GT-3′) as per the manufacturer's protocol. A three-step
temperature program was applied for the ampliﬁcation of OATP2B1
and GAPDH: initial denaturation (95 °C) for 10 min and then 94 °C for
15 s, 58 °C for 30 s and 72 °C for 30 s for 40 cycles.
2.6. OATP2B1 small interfering RNA (siRNA) and siRNA transfection
Three kinds of siRNA (117442, 120018 and 120019) targeted to
different regions of the OATP2B1 gene and nontargeting siRNA
(AM4635) as a negative control were purchased from Ambion.
Delivery of siRNAs into A549 cells was performed by reverse
transfection methods as per the manufacturer's protocol. One μL
siPORT NeoFX (Ambion) and 49 μL Opti-MEM I medium (Invitrogen)
were mixed and incubated at room temperature for 10 min. Two μM
siRNA was diluted to 300 nM with Opti-MEM I medium. Fifty μL
diluted siPORT NeoFX and 50 μL diluted siRNA were mixed and
incubated for 10 min, and then these complexes were dispensed into
the wells of a 24-well plate and 400 μL of suspended A549 cells
(1.5×105 cells/mL) was transferred. Following siRNA transfection
(24 h), the medium was replaced with fresh normal growth medium
and then the cells were used for analysis and experimentation at the
times indicated.
2.7. Analytical procedures
AMD was determined using an HPLC system equipped with a
Shimadzu LC liquid chromatograph pump and UV detector. The
Fig. 2. Concentration-dependence of AMD uptake by A549 cells. The uptake of AMDwas
measured for 5 min at pH 5.0 at 37 °C (closed circles) or 4 °C (open circles). Triangles
represent the difference between the uptake at 37 °C and that at 4 °C. Each point
represents the mean±S.D. of 3 independent experiments.
Table 2
Inhibitory effects of various compounds on the uptake of AMD by A549 cells.
Inhibitor Concentration AMD uptake
















A549 cells were incubated with AMD (25 μM) for 5 min at 37 °C at pH 5.0. Each value is
the mean±S.D. of 3–9 independent experiments.
⁎ Signiﬁcantly different from control (pb0.05).
⁎⁎ Signiﬁcantly different from control (pb0.01).
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Kanto Chemical). A mobile phase containing 9.5 mM H3PO4:
acetonitrile (1:1, v/v) was used. Column temperature and ﬂow rate
were 40 °C and 1.0 mL/min, respectively. The wavelength for
detection of AMD was 242 nm. Radioactivity was determined using a
liquid scintillation counter (Packard, 1600TR). Protein was measured
by the method of Lowry et al. with bovine serum albumin as a
standard [29].
Statistical signiﬁcance was evaluated using ANOVA followed by
Dunnett test, and a value of Pb0.05 was considered signiﬁcant.
Nonlinear regression analysis was performed by using Origin®
(version 6.1J).
Kinetic parameters were obtained using the following equation:
v = Vmax × s= Km + sð Þ + Kns × s
where v is the uptake rate of compounds, s is the compounds
concentration in the medium, Km is the Michaelis–Menten constant
and Vmax is the maximam uptake rate. Kns represents non-saturable
uptake clearance.
3. Results
3.1. Uptake of AMD by A549 cells
In the ﬁrst part of this study, AMD uptake by A549 cells was
measured. Fig. 1 shows the time courses of the uptake of AMD. The
uptake of AMD linearly increased for 10 min after the start ofFig. 3. Effects of extracellular cations on the uptake of AMD by A549 cells. A549 cells
were incubated with AMD (25 μM) for 5 min at pH 5.0 at 37 °C. The results were
normalized by the uptake in the presence of Na+. Each column is expressed by themean
with S.D. of 3 independent experiments.incubation. Thus, the initial uptake was evaluated for 5 min. To obtain
kinetic parameters, the concentration-dependence of the uptake of
AMD by A549 cells was examined. The uptake of AMD after subtraction
of the value at 4 °Cwas saturated (Fig. 2) and the apparent Km and Vmax
values were 66.8±30.3 μM and 49.7±9.7 nmol/mg protein/5 min,
respectively. To characterize the transport mechanisms of AMD, the
effect of replacement of Na+with various cations on the uptake of AMD
was examined.WhenNa+was replacedwithK+, Li+, Rb+orN-methyl-
D-glucamine, the uptake of AMD was not signiﬁcantly different from
that in the presence of Na+ (Fig. 3), suggesting an Na+-independent
transport mechanism.
3.2. Effects of various compounds on the uptake of AMD by A549 cells
To determine the mechanism of AMD transport, the inhibitory
effects of various compoundswere examined (Table 2). Since AMD is a
cation, ﬁrstly, we investigated whether substrates of organic cation
transporters (OCTs) inhibited the uptake of AMD. Tetraethylammo-
nium (TEA) and choline, substrates of OCTs, did not inhibit the uptake
of AMDbut rather slightly increased it. Cimetidine also had no effect on
AMD uptake. On the other hand, the uptake of AMD was signiﬁcantly
inhibited by the OATP substrates, sulfobromophtalein (BSP), estrone-
3-sulfate (E-3-S), dehydroepiandrosterone-sulfate (DHEAS), benzyl-
penicillin and pravastatin but not by triiodothyronine (T3) and
estradiol-17β-glucuronide (E217βG). 4,4′-diisothiocyanostilbene-
2,2′-disulfonic acid (DIDS), indomethacin and valproic acid also
exhibited inhibitory effects, and taurocholate slightly inhibited the
uptake of AMD. However, the organic anion transporter (OAT)
substrate p-aminohippurate (PAH) had no effect on the uptake of
AMD. The inhibition proﬁles were similar to the inhibitory effects of
those compounds on OATP2B1-mediated E-3-S transport [27].Fig. 4. Expression of OATP transporters in A549 cells. RT-PCR was performed with total
RNA isolated from A549 cells. Speciﬁc primers were used to detect genes as described in
Materials and methods.
Fig. 5. (A) Time course of [3H]E-3-S uptake by A549 cells. The uptake of [3H]E-3-S
(5.0 nM) was measured at pH 7.4 (open circles) or pH 5.0 (closed circles) at 37 °C. Each
point represents the mean±S.D. of 3 independent experiments. (B) Concentration-
dependence of [3H]E-3-S uptake by A549 cells. The uptake of [3H]E-3-S was measured
for 2 min at pH 5.0 at 37 °C. Dotted and solid lines represent the nonsaturated and
saturated uptakes, respectively, obtained from nonlinear least-square regression
analysis of the total uptake (closed circles). An Eadie–Hofstee plot of [3H]E-3-S uptake
after subtraction of the estimated non-saturable component is shown in the inset. Each
point represents the mean±S.D. of 3 independent experiments.
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To investigate subtypes of OATPs involved in AMD transport in
A549 cells, the mRNA expressions of several OATPs were investigated
by RT-PCR analysis. As shown in Fig. 4, RT-PCR analysis demonstrated
mRNA expression of OATP2B1 and 1B3 in A549 cells. The mRNA
expressions of 3A1 and 4A1wereweak and those of 1A2 and 1B1were
not detected. Taking the inhibition proﬁles of the uptake of AMD into
consideration, we suggest that OATP2B1 is a candidate to mediate the
uptake of AMD in A549 cells among these OATPs.Table 3
Effects of various compounds on [3H]E-3-S uptake by A549 cells.
Compound Concentration [3H]E-3-S uptake
mM % of control
E-3-S (unlabeled) 0.5 57.0±3.8⁎⁎
BSP 0.5 56.7±3.4⁎⁎
DHEAS 0.5 67.2±9.6⁎⁎
A549 cells were incubated with [3H]E-3-S (5.0 nM) for 2 min at pH 5.0 at 37 °C. Each
value represents the mean±S.D. of 3 independent experiments.
⁎⁎ Signiﬁcantly different from control (pb0.01).3.4. Uptake of E-3-S by A549 cells
We then examined the kinetic analysis of the uptake of [3H] E-3-S,
which is a model substrate of OATP2B1, in A549 cells. The uptake of
[3H]E-3-S by A549 cells at pH 5.0 was higher than that at pH 7.4. (Fig.
5A) This result is consisted with the previous report that OATP2B1 has
higher activity at acidic pH than neutral pH [30]. Furthermore, theFig. 6. Analysis of siRNA-mediated silencing of OATP2B1 mRNA expression by
quantitative real-time RT-PCR at 48 (A), 72 (B) and 96 h (C) after transfection.
Expression analyses were performed using three different siRNA constructs, OATP2B1-
a, b and c. OATP2B1 mRNA expression levels were normalized to GAPDH in A549 cells.
Each column represents the mean with S.D. of 3–6 independent experiments. ⁎;
signiﬁcantly different from negative control siRNA (pb0.05). ⁎⁎; signiﬁcantly different
from negative control siRNA (pb0.01).
Fig. 7. Effect of OATP2B1 siRNA on AMD uptake in A549 cells at 48 (A) and 72 h (B) after
transfection. A549 cells were treated with negative control siRNA or OATP2B1 siRNA.
The uptake studies were performed at 48 (A) and 72 h (B) after transfection. The uptake
of AMD (25 μM) was evaluated for 5 min at pH 5.0 and expressed as the difference
between the uptake at 37 °C and that at 4 °C. The results were normalized by the uptake
in the negative control siRNA-treated A549 cells. Each column represents themeanwith
S.D. of 3 independent experiments. ⁎; signiﬁcantly different from negative control
siRNA (pb0.05).
Fig. 8. Effectof BSPon theuptakeofAMDbynegative control siRNA- andOATP2B1 siRNA-
treated A549 cells. The uptake studies were performed at 72 h after transfection. The
uptake of AMD (25 μM)was evaluated at 5min at pH 5.0 and expressed as the difference
between theuptakeat 37 °C and that at 4 °C. The resultswerenormalized by theuptake in
the negative control siRNA-treated A549 cells. Each column represents the meanwith S.
D. of 3 independent experiments. ⁎⁎; signiﬁcantly different from the absence of BSP
(pb0.01). †; signiﬁcantly different from negative control siRNA (pb0.05).
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BSP and DHEAS, which are substrates for OATP2B1 (Table 3). Initial
uptake (2 min) of [3H]E-3-S by A549 cells at concentrations ranging
0.5 to 20 μM exhibited saturation at pH 5.0. Eadie–Hofstee plots
showed a single straight line, and the Km and Vmax were 8.8±2.5 μM
and 79.2±10.4 fmol/mg protein/2 min, respectively (Fig. 5B).
3.5. Effects of OATP2B1 siRNA on OATP2B1 mRNA expression and AMD
uptake in A549 cells
To investigate whether OATP2B1 knockdown induces any change
in OATP2B1 mRNA expression and AMD uptake in A549 cells,
quantitative real-time RT-PCR experiments were performed to
quantify OATP2B1 mRNA values at 48, 72 and 96 h after siRNA
transfection. In this study, three different siRNA constructs targeted to
the OATP2B1 gene, OATP2B1-a, b and c, were used. The negative
control siRNA did not affect OATP2B1 mRNA expression compared
with that in cells not transfected with siRNA at 48, 72 and 96 h after
transfection (data not shown). Therefore, we used this siRNA as a
negative control in this study. Application of three siRNAs for OATP2B1
resulted in a considerable decrease in OATP2B1 mRNA expression
level at 48 h after transfection (Fig. 6A). The gene silencing effects of
OATP2B1-b and c continued at least until 72 h after transfection (Fig.
6B), whereas those effects appeared to be attenuated at 96 h (Fig. 6C).
Thus, we investigated the effects of OATP2B1 siRNA on AMD uptake at48 and 72 h after transfection. Since the negative control siRNA did not
affect AMD uptake compared with that in untreated A549 cells, the
results of AMD uptake were normalized to negative control siRNA-
treated A549 cells. The uptake of AMD by A549 cells was decreased by
transfection of the three different siRNAs at both 48 (up to about 30%)
(Fig. 7A) and 72 h (up to about 40%) (Fig. 7B) after transfection. The
inhibitory effects at 72 h seemed to be stronger than those of 48 h. To
clarify the involvement of OATP2B1 in the inhibitory effects of OATP
substrates, as shown in Table 2, the effect of BSP on AMD uptake in
OATP2B1-knockdown A549 cells was examined. The AMD uptake was
determined at 72 h after transfection, and we used 4 μM BSP, which is
a concentration close to IC50 of BSP (5.3±0.2 μM) on AMD uptake by
A549 cells. AMD uptake in OATP2B1 siRNA-treated A549 cells was not
inhibited by BSP, whereas that in negative control siRNA-treated A549
cells was signiﬁcantly inhibited (Fig. 8). We conﬁrmed the effect
OATP2B1 knockdown on the mRNA expression level of OATP1B3, 3A1
and 4A1 by Real-Time PCR. OATP2B1 siRNA did not reduce these
OATPs mRNA expression level (data not shown).
4. Discussion
AMD is a highly effective drug for the treatment of cardiac
dysrhythmias, but AMD has several side effects. Pulmonary toxicity is
the most life-threatening and limits clinical use of AMD [31–33]. In
this study, we focused on the strong tendency of AMD to accumulate
in lung tissue and we investigated the AMD uptake mechanism using
A549 cells. A549 cell is a model of the type II alveolar epithelial cell
(AEC), which possesses many lung functions, including antioxidant
defense and lung speciﬁc phospholipids comprising pulmonary
surfactant. In addition, AECs are stem cells for alveolar epithelial
repair after lung injury and during normal AEC turnover [34].
Dysfunction of the AEC repair system or cytotoxicity for AECs may
lead to acceleration of collagen deposition and lung ﬁbroblast
proliferation [35]. AMD-induced cytotoxicity for AECs might be a
critical factor in the pathogenesis of AIPT [34,35]. Therefore, carrier-
mediated AMD uptake, which we found in this study, might lead to an
increase in the incidence of AIPT. This mechanism might also be
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characterized this mechanism considering as a new aspect of
pharmacokinetic feature of AMD.
Although AMD charges positively under the physiologic condition,
the uptake of AMD was inhibited by OATP substrates, BSP, E-3-S and
DHEAS [36–38] (Table 2). These anionic compounds are also OAT
substrates, but PAH,which is a typical substrate of OATs, did not exhibit
an inhibitory effect, indicating that AMD uptakewas affected by OATPs
but not by OATs. On the other hand, T3, a typical substrate of most
OATPs [36–39], had no effect on the uptake of AMD. Although mRNA
expression of several OATPs (OATP2B1, 3A1, 4A1 and 1B3) was
observed in A549 cells (Fig. 4), only OATP2B1 among human OATPs
does not transport thyroid hormones (OATP2A1, 5A1 and 6A1 have not
been fully investigated) [39,40]. E217βG, which is a substrate or an
inhibitor of OATP1B3 but not OATP2B1 [41], did not exhibit an
inhibitory effect on AMD uptake, indicating that OATP1B3 has little
inﬂuence on AMD uptake. OATP2B1 has been reported to be expressed
in a variety of tissues, including the lung [28,40], and BSP, E-3-S and
DHEAS are well-known substrates for OATP2B1 [40]. The Km value for
[3H]E-3-S uptake by A549 cells is similar to the reported Km value for
[3H]E-3-S uptake by HEK293 cells expressing OATP2B1 at pH 5.0
(13.1±3.2 μM) (Fig. 5) [30]. These results indicate that OATP2B1 is
active in A549 cells. In this study, BSP inhibited the uptake of AMDwith
an IC50 value of 5.3±0.2 μM (data not shown). This IC50 value is not
greatly different from the reported Km value for BSP uptake by
OATP2B1-injected Xenopus laevis oocytes (0.7 μM) [40]. Thus, we
investigated the effects of other OATP2B1 substrates (benzylpenicillin
and pravastatin) and inhibitors (taurocholate, DIDS, indomethacin and
valproic acid) [27,42]. All of the tested compounds except taurocholate
signiﬁcantly inhibited AMD uptake (Table 2). The transport mechan-
ism of AMD was Na+-independent (Fig. 3), and this is also consistent
with the fact that OATPs are Na+-independent transporters [36–38].
Based on these results, we hypothesized that OATP2B1 is involved
in the uptake of AMD in A549 cells. Due to the low solubility of AMD, it
was difﬁcult to perform further kinetic analysis. Thus, to investigate
whether OATP2B1 mediates AMD uptake, OATP2B1 knockdown in
A549 cells was examined by using siRNA.
The siRNAs targeted to the OATP2B1 gene reduced OATP2B1 mRNA
expression level in A549 cells up to about 50% (Fig. 6) and the uptake of
AMD up to about 40% (Fig. 7). Since OATP2B1 siRNA did not reduce
other OATPs mRNA expression level (data not shown), it is considered
that the decrease of AMD uptake in OATP2B1 siRNA-treated A549 cells
was the result of OATP2B1 knockdown, and OATP1B3, 3A1 and 4A1 did
not affect AMD uptake. In addition, the inhibitory effect of BSP on AMD
uptake was attenuated in OATP2B1 siRNA-treated A549 cells, com-
pared to that in negative control siRNA-treated A549 cells (Fig. 8),
indicating that the inhibitors of AMDuptake, as shown inTable 2,might
inhibit OATP2B1-mediated AMD uptake. Although general Oatp/OATP
substrates aremainly anionic amphipathicmolecules, there are several
Oatps/OATPs that transport organic cations (e.g., N-(4,4-azo-n-
pentyl)-21-deoxyajmalinium and N-methylqunidine) [37,43]. We
speculate that OATP2B1 also transports or interacts with cationic
compounds like AMDaswell as anionic compounds. These resultsmay
provide new insight into OATP2B1 function. Although the apparent Km
value of AMD transport in A549 cells was 66.8±30.3 μM, the Km value
for transport of AMD by OATP2B1 was not obtained in this study. In
addition, the involvement of uptake mechanisms other than OATP2B1
cannot be excluded. Further experiments are required to clarify the
accurate kinetic parameter values for transport of AMD by OATP2B1
and to compare the Km value of AMD to the therapeutic serum level of
AMD (2.99 μM) with the general dose of 400 mg/day [44].
In clinical practice, it is important to be aware of the potential of
drug–drug interactions andvariations in the pharmacological effects of
drugs bygenetic polymorphisms. One single nucleotide polymorphism
in the OATP2B1 gene was reported to inﬂuence the transport activity
[45]. Alteration of AMD uptake activities in the lung by geneticpolymorphisms could cause interindividual difference in AIPT inci-
dence. In addition, recent studies have shown that several drugs are
recognized by or interact with OATP2B1 [43,46–48]. It is likely that the
transport process of AMD is inhibited by co-administered drugs,
resulting in alteration of AMD pharmacokinetics. The information of
the AMD uptake mechanism obtained in this study will be useful for
resolving the difﬁculty in control of AMD serum level [9].
In summary, AMD was transported by a carrier-mediated system
into A549 cells, and OATP substrates and inhibitors inhibited the AMD
uptake. Transport of AMD by A549 cells is mainly mediated by
OATP2B1. The newly found pharmacokinetic feature of AMDmay be a
key to explain the mechanism of AMD accumulation in the lung and
the high incidence of AIPT.References
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